泰恩康：CKBA乳膏申报儿童白癜风临床试验取得受理通知书

Core Viewpoint - The announcement indicates that Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., a subsidiary of Tiancong, has received an acceptance notice from the National Medical Products Administration for a Phase II clinical study application regarding CKBA cream for treating non-segmental vitiligo in children aged 2 to 12 years [1] Group 1 - The clinical study will assess the safety, tolerability, efficacy, and pharmacokinetic characteristics of CKBA cream [1] - The study design is a multicenter, randomized, double-blind, placebo-controlled trial [1]